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ABSTRACT  
   
Sleep is an essential human function. Modern day society has made it so that 
sleep is prioritized less and less. Professionals in critical positions such as doctors, nurses, 
and emergency medical technicians can often have hectic schedules that are unforgiving 
toward sleep due to the increase in shift work that dominates these fields. Sleep deficits 
can have detrimental effects on one’s psyche and mood. Depression and anxiety both 
have high comorbidity rates with insomnia because of sleeping deficits. Transdermal 
Electrical Nerve Stimulation (TENS) offers a potential solution to improving sleep 
quality and mood by modulating the ascending reticular activating system (RAS). This 
system starts in the anterior portion of the head with trigeminal nerve branches and is 
stimulated using a 500-550 Hz waveform.  
In this experiment Positive Affect and Negative Affect Schedule (PANAS) scores 
are recorded daily to monitor mood differences between pre and post treatment (TENS vs 
Sham). PANAS scores were found to be insignificant between groups. Pittsburgh Sleep 
Quality Index (PSQI), and Fitbit were chosen to study perceived sleep, and objective 
sleep. Both PSQI, and Fitbit found insignificant differences between TENS and Sham. 
Finally, the Beck Depression and Beck Anxiety Inventories were administered weekly to 
determine if there are immediate changes to depressive and anxiety symptom, after a 
week of treatment (TENS vs Sham). A significant difference was found between the pre 
and post of the TENS treatment group. The TENS group was not found to be 
significantly different from Sham, potentially the result of a placebo effect. These results 
were found with n=10 participants in the TENS treatment group and n=6 in the sham 
group.  
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CHAPTER 1 
INTRODUCTION 
Sleep is an essential part of everyday life, yet society is developing in such a way 
that sleep is prioritized less and less. Ferrie et al. propose that society is quickly 
becoming a 24/7 endeavor with people working at all hours (Ferrie,1). The increase in 
shift work has led to an increase in sleep disorders with over 30% of adults reporting 
some type of insomnia (Ferrie,1). Policemen, doctors, and even astronauts suffer from 
sleep deprivation, which can lead to a critical drop in performance ability (Gordon,2). 
Doctors and nurses that committed to a full overnight shift had a 16% decrease in 
performance from the beginning of their shift to the end of their on-call shift (Gordon,1). 
The American Sleep Association reports that 10-15% of fatal car accidents were caused 
by a drowsy driver (Sleep Statistics,1). Taylor et al. have found that insomnia has proven 
comorbidities with depression and anxiety (Taylor,1). Those with insomnia were almost 
10 times as likely to have depression, and 17 times as likely to have anxiety (Taylor,1). It 
is apparent that solutions need to be found to help people correct their sleep patterns, and 
remedy sleep conditions. A solution worth exploring is transdermal electrical nerve 
stimulation of key cranial nerves. 
Non-invasive methods of cranial nerve stimulation have been heavily studied and 
have been present in the United States of America since the 1960’s when the first use of 
cranial electrotherapy stimulation (CES) was used and referred to as “Electrosleep” 
(Guleyupoglu,1). The United States Food and Drug Administration (FDA) classified CES 
devices as class III requiring pre-market approval in 1976 (Federal Register, 3752). After 
public hearings, the FDA reclassified CES devices as class II with special controls 
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(Federal Register, 3753). Specifically, any device that is used for the treatment of 
insomnia and anxiety was classified as a class II device as the devices have shown 
general effectiveness for use in these areas (Federal Register, 3753). CES devices for use 
in depression are still classified as class III and require pre-market approval (Federal 
Register, 3753).  
The Neuros device manufactured by Cerevast is a CE, European Conformity, 
class IIa CES device and is the primary device used in this experiment (Cerevast,2). CES 
devices operate via TENS and apply electrical current to the user’s head to stimulate 
cranial nerves. Branches of the trigeminal nerve that run through the anterior portion of 
the head are the primary target of Neuros (Cerevast,3). These branches send signals to the 
ascending reticular activating system (RAS), a system that receives sensory input and 
transmits the information to the cortex to regulate sleep wake cycles, arousal, and 
alertness (Cerevast 3).  The RAS originates in the upper brain stem and has connections 
to key structures such as the pons, thalamus, and terminates at the cortex (Schwarz,2). 
The RAS includes the pedunculopontine nucleus (PPN) the locus coerleus (LC), and the 
raphe nuclei (Cerevast,3). These structures are responsible for gate regulation and 
triggering of sleep/wake cycles, arousal, and awareness due to their connections to and 
modulation of the reticular nucleus of the thalamus (Schwartz,2). To stimulate the RAS 
branch, the Neuros stimulator targets the trigeminal sensory nuclear complex (TSNC) by 
stimulating the trigeminal nerve branches located in the anterior portion of the head 
(Cerevast, 3). The fact that these branches can be stimulated non-invasively is a large 
advantage to the device, making it user friendly, and most importantly user safe 
(Cerevast,4). 
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The experiment was designed to replicate and extend research on the impact of 
TENS on sleep and mood in the short term as compared to a sham condition during a 
short-term two-week intervention. The idea that the Neuros can be used to correct sleep 
and mood in the short term is a novel approach, rather than using stimulation as a 
solution to insomnia. The idea here being that it can be used to lessen the symptoms of 
stress based temporary insomnia. Sleep was measured using the traditional Pittsburgh 
Sleep Quality Index, and the Fitbit-Charge 2 sleep quality module. This module provided 
values for key metrics such as: time in minutes to sleep onset measured from the 
completion of stimulation, wake after sleep onset (WASO) total minutes, wake up 
quantity, and total sleep duration. Mood impacts were measured using three assessments: 
the Positive Affect and Negative Affect Schedule, the Beck Depression Inventory, and 
the Beck Anxiety Inventory. A product by the name of Neuros manufactured by Cerevast 
was used in the treatment condition for subjects. 
It is hypothesized that WASO, and wakefulness periods of the sleep cycle will 
reduce in treatment patients. PANAS scores are expected to tend toward high positive 
affect values and lower negative affect values. Beck Anxiety and Beck Depression 
Inventory scores are expected to be in the minimum, or mild ranges of their expected 
scales after a week of stimulation. 
The second experiment involved collecting audio files from participants every day 
to determine the accuracy in mood reading APIs such as IBM Watson or Beyond Verbal. 
Scores from these two apps would be used and compared against the clinical mood 
assessments to determine efficacy of the technology. These results are not presented in 
this Master’s thesis. 
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A tertiary aim for this study was to develop a workflow to scale the study to large 
scale by developing a software backend for the study with a company named Trialomics. 
A backend was created that administered and scored surveys, recorded stored and parsed 
audio files, and aggregated data from Fitbits that were linked to participants individual 
accounts. By having a software backend that served as a one stop area for all study 
materials, it is anticipated that subjects will be more compliant and easier to train. 
Creating a backend that stores data digitally allows the scaling of the study to obtain 
larger participant populations. 
The work presented in this master’s thesis builds upon the work of several pre-
print open source papers that aim to understand the effects of TENS and determine its 
usability. In Paneri et al 2016, 100 subjects received a TENS or sham treatment once a 
day for 5 days (Paneri,5). The main goal of the study was to determine the occurrence of 
adverse events during TENS (Paneri,1). It was found that there was no significant 
statistical difference to suggest that active TENS treatment had a higher rate of adverse 
events than sham in areas such as: mildly tingling (during session), mild burning (during 
session), itching (within session), headaches (within session), and headache (between 
sessions) (Paneri, 11-19). Mild burning and mild tingling reported higher in sham groups 
than in either treatment group (Cerevast,5).  Data on sensations felt were also recorded in 
the current investigation but is not reported in this document. 
Tyler et al. conducted a series of experiments designed to determine if TENS can 
lower criteria on the Profile of Mood State (PMOS) survey (Tyler,1). The stimulator used 
in this experiment were a predecessor to the Neuros used in the experiments outlined in 
this paper called Thync that had similar waveform parameters (Tyler,13). Subjects were 
  5 
given a resting period, a treatment period, then asked to fill out the PMOS (Tyler,13-14). 
This experiment looked at negative sub-scales such as: tension-anxiety, anger-hostility, 
depression-dejection, fatigue-inertia, and vigor-activity (Tyler,3). The data showed that 
TENS significantly reduced stress-tension in comparison to sham groups (Tyler,3). In the 
current study, Beck Anxiety and PANAS surveys are used to monitor mood positivity 
and negativity as well as anxiety to determine if the results seen in the Tyler investigation 
are supported. A key difference between the two studies is that Tyler et. all measure an 
immediate before and after for participant stimulation, in this investigation weekly 
change is looked at for PANAS and Beck Anxiety. 
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CHAPTER 2 
METHODS 
Participants 
 All participants in this study were human volunteers using protocols that were 
approved of by the Arizona State University Institutional Review Board (STUDY 
00008350) under the office of Research Integrity and Assurance. Participants were 
recruited primarily from the Tyler Lab research subject pool and word or mouth referrals.  
Inclusion criteria. General inclusion criteria included: adult males and females 
aged 18-65, able to give consent, and a full-time worker, full-time student, OR the 
combination of a part-time student and worker. All subjects were screened using an 
online questionnaire through REDCap software and brief interview.  
Exclusion criteria. Potential participants were excluded from the study if they 
endorsed any of the following criteria: no daily access to a PC desktop/laptop or 
smartphone with Internet access, currently undergoing treatment or medication for 
neurological or psychological disorder, including addiction, a medical implant (such as a 
pacemaker, cochlear implant, brain stimulation device), history of migraines or frequent 
headaches, history of panic attack or acute anxiety disorder, history of fainting (vaso-
vagal syncope or neurocardiogenic syncope), Raynaud's disease,  tempomandibular joint 
(TMJ) disorder or other facial neuropathy,  history of concussions or brain injury, history 
of significant face/head injury or cranial or facial metal plate or screw implants, history 
of hospitalization for neurological or psychological disorder, recent hospitalization for 
surgery/illness, vision or hearing that is uncorrectable (corrected vision or hearing is 
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okay), pregnant, recent drug or alcohol treatment, high blood pressure, heart disease, or 
diabetes, a diagnosed sleep disorder, or taking prescription medication for sleep. 
Eligible subjects were scheduled for individualized training sessions where the 
study and its expectations were thoroughly discussed, and consent was acquired prior to 
experimentation. All subjects were provided necessary training on the various hardware, 
apps, and surveys that they would be using. Participants were randomly assigned to the 
treatment or sham conditions.  
Assessments 
 Positive and Negative Affect Schedule (PANAS). The state version of the 
PANAS is a self-report 20-item questionnaire that assesses momentary positive and 
negative emotions on a 1-5 point Likert-Scale (Krohne, Egloff, Kohlmann, & Tausch, 
1996). PANAS scores were collected every evening to understand patient mood, and how 
it changed daily. Daily scores were averaged to produce a Baseline (day 1), Pre-treatment 
(day 2-8), and Post-treatment (day 9-14) score.  Ultimately these scores can show how 
subjects’ moods are variant in the baseline and whether pTES has effects that make their 
mood more consistent, or improves their mood, in the short term.  
 Beck Depression Inventory (BDI-II). The BDI-II is a 10-minute, 21-item, self-
report questionnaire assessing depression symptoms over a one week period using 
statements assigned a 0-3 point value (Beck, 1996).  The BDI-II scores were collected at 
three time points: Baseline (day 1), Pre-treatment (day 8), and Post-treatment (day 14) to 
determine whether there was an effect from the stimulation on depression among the 
participants.  
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 Beck Anxiety Inventories (BAI). The BAI is a 10-minute, 21-item, self-report 
questionnaire assessing anxiety symptoms over a one week period using a 0-3 rating 
scale corresponding to a response of "not at all", "mildly", "moderately", and "severely"   
(Beck, 1990).  The BAI scores were collected at three time points: Baseline (day 1), Pre-
treatment (day 8), and Post-treatment (day 14) to determine whether there was an effect 
from the stimulation on anxiety among the participants.  
 Pittsburgh Sleep Quality Index (PSQI). The PSQI is a seven domain (19 item) 
self-rated questionnaire evaluating usual sleep habits during the last week. The seven 
domain scores including: subjective sleep quality, sleep latency, sleep duration, sleep 
efficiency, daytime dysfunction, sleep fragmentation, and use of sleep aid medications; 
and combine to provide a global sleep quality index score. The possible scores range 
from 0–21. PSQI scores were collected at three time points: Baseline (day 1), Pre-
treatment (day 8), and Post-treatment (day 14) to determine whether there was an effect 
from the stimulation on sleep among the participants. All surveys are administered and 
processed for scoring in a database created for the survey by Picard.io, a HIPPA 
compliant software company. Picard’s integration is explained in figure 1. An example of 
Picard’s user interface is seen in figure 2. 
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Neuros Model 1 Feedback Questionnaire. This is a 5-item self-report 
questionnaire to elicit user feedback about the Neuros the manual/tutorials, stimulation 
intensity settings, operational ease, sensation/tolerability, and effectiveness. This 
assessment was emailed to participants following the completion of the study.     
 
 
 
 
Figure. 1. Picard Integration to Study Design. A block diagram explaining the needs 
Picard fills in the study. Rather than administer all the surveys by paper, Picard builds a 
database that holds and scores the surveys. An additional benefit of Picard is its ability to 
integrate multiple platforms such as directly from user, Fitbit, and Cerevast’s Neuros 
App, and store user data together. 
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Devices 
Fitbit. Fitbit was used as a method of actigraphy to determine participant sleep 
quality. Four metrics were collected: time in minutes to sleep onset measured from the 
completion of the Neuros session (only examined during days 8-14), wake after sleep 
onset (WASO), quantity of wakeups, and sleep duration. According to Fitbit 
documentation, the variable “startTime” is an indicator of when the user fell asleep. Time 
in minutes to sleep onset was measured from the time the Neuros stimulation began to the 
time that Fitbit “startTime” begins, 15 minutes are subtracted from this value because that 
is the length of one Neuros session. WASO was collected using a variable called 
“ToFallAsleep”. Quantity of wakeups was measured using the variable 
Figure. 2. Example Compliance Screenshot. An example how integrating all the user data 
into a single table can be used to check compliance of individual participants. Picard also 
provides the ability to email participants in the event they are at risk of failing to comply. 
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“summary.awake”. Lastly, total sleep duration was measured with a variable called 
“duration”. Participants were required to wear the Fitbit during sleep throughout the 
study (day 1-14 ). Scores were averaged at three time points for the above metrics: 
baseline (day 1), Pre-Treatment (days 2-7), Post-Treatment (days 8-14). 
Neuros.  The Neuros device, seen in figure 1, manufactured by Cerevast is a CE, 
European Conformity, class IIa CES device that uses low-energy, pulsed electrical 
stimulation to enhance relaxation and sleep [7,8]. The stimulation created by the 
hardware was a biphasic, or pulsed, current of 4 mA on average with a frequency of 500-
550 Hz. Stimulation levels were adjustable, and each participant was told to adjust to 
their comfort level. Participants were required to use the study device for 15 minutes 
prior to bed during the second week of the study (day 8-14). Figure 3 shows the 
placement of Neuros on the participant. 
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Figure. 3. Neuros Placement Graphic. This graphic was used with permission from 
Cerevast. Placement of the Neuros as recommended by the manufacturer Cerevast, 1 
shows the Neuros module which contains the electronics, rechargeable battery, and 
connects to the limited use strip electrode assembly, or strip, at arrow 2. The strip 
contains the electrodes needed to stimulate trigeminal nerves (V1, V2) and the cervical 
nerves near vertebrae C2 and C3. 
  13 
CHAPTER 3 
RESULTS 
The primary aim for this study was to determine effect of TENS on sleep habits 
and quality. The PSQI is a clinically validated self-reported sleep assessment that was 
given to participants weekly, and the results of this survey are shown in table 1. The 
results of the self-reported sleep assessment show that there were no significant 
differences between groups initially. The overall time, group interaction shows 
significance with a p-value of 0.013 but there were no significant changes between 
groups for TENS treatment versus sham treatment and there were no significant 
differences for before and after results for active treatment but sham treatment 
approaches significance. The TENS treatment had no significant effects on perceived 
sleep quality in a week. Fitbit data was also recorded, and several metrics were used to 
determine objective quantitative sleep data. Table 2 shows a summation of the statistics 
regarding Fitbit. Fitbit echoes the results of the PSQI with only light sleep minutes being 
statistically significant in the time, group interaction. There were no significant 
differences between groups for any of the metrics measured with Fitbit. There was a 
significant decrease in light sleep for the sham group in time, but this was not significant 
compared to the active treatment group. 
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Table. 1. 
Results of a mixed model repeated measures statistical analysis. Time and Group were 
treated as covariates, with treatment (TENS or Sham) as independent variables and 
results of the PSQI as the dependent variable. Significance was seen in the time group 
interaction with a p-value of 0.013, and near significance was seen in the time 
comparison of the sham group. Neither result was statistically significant between 
groups. 
Table. 2.  
Results of a mixed model repeated measures statistical analysis. Time and Group were 
treated as covariates, with treatment (TENS or Sham) as independent variables and 
results of the Fitbit metrics as the dependent variables. Significance was seen in the time 
group interaction of light sleep duration with a p-value of 0.03 and was seen in the time 
comparison of the sham group with a p-value of 0.014. Neither result was statistically 
significant between groups. 
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Quality of life improvement was another aim for the study using Positive and 
Negative Affect Schedule scores to determine day to day differences, if any, from figure 
4 and figure 5. The PANAS results report that there are no statistical differences between 
the sham group and treatment group for positive mood scores or negative mood scores. 
There were no significant differences prior to administering the treatments, nor were 
there significant differences after the participants began to be monitored. These results do 
show that positive affect trended toward being statistically significant between the two 
groups, according to the mixed model repeated measure results in table 3. Both had a 
mean increase in positive affect, but the treatment group tends toward having a greater 
impact. Figures 4 and 5 show the group interactions overtime. Positive affect trends 
positively, away from baseline and sham that trend negatively and follow each other. 
These graphs have no statistically significant values but offer an alternative way to see 
the data. It is also interesting to note that the negative affect graph shows that the active 
treatment group stay, on average, below the sham group. 
 
 
 
 
 
Table. 3. Results of a mixed model repeated measures statistical analysis. Time and 
Group were treated as covariates, with treatment (TENS or Sham) as independent 
variables and results of the PANAS positive affect (PANAS+) and negative affect 
(PANAS-) as the dependent variables. Near significance was seen between groups in the 
PANAS+ scores. 
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Figure. 4. A plot of positive affect PANAS scores over duration of the study. Baseline 
points are averaged amongst all 16 participants while TENS (Treatment) and Sham only 
include their respective n’s 10 and 6. Error bars were created with one standard deviation 
of the averages, and a trend line was made to represent the direction the baseline is 
expected to continue. 
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Depression and anxiety are co-morbidities as discussed in the introduction of this 
thesis. Therefore, both were examined using the Beck Depression and Beck Anxiety 
Inventories. The results for these surveys are shown in table 4. Overall for the Beck 
Depression and Beck Anxiety groups there were no statistical differences between sham 
and treatment groups. An interesting result is a statistically significant difference between 
pre and post Beck Anxiety Inventory scores for TENS treated participants. The TENS 
group did have reduced anxiety levels, but these were not statistically significant when 
compared to the sham group. 
 
 
Figure 5. A plot of negative affect PANAS scores over duration of the study. Baseline 
points are averaged amongst all 16 participants while TENS (Treatment) and Sham only 
include their respective n’s 10 and 6. Error bars were created with one standard deviation 
of the averages, and a trend line was made to represent the direction the baseline is 
expected to continue. 
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Table. 4. Results of a mixed model repeated measures statistical analysis. Time and 
Group were treated as covariates, with treatment (TENS or Sham) as independent 
variables and results of the Beck Depression Inventory and Beck Anxiety Inventory score 
metrics as the dependent variables. Significance was seen in the time group interaction of 
both inventories with a p-values of 0.038 and .01. Neither inventory was significant 
between groups, but the active sham has significance between pre and post in the time 
group. 
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CHAPTER 4 
DISCUSSION 
PSQI 
An interesting observation in the PSQI data can be seen in the time group 
interaction. Active PSQI scores trend negatively (higher scores) while sham scores fail to 
trend at all. One of the recurring weaknesses of the study is the number of individuals 
enrolled. It could be that there is not enough of a sample size to determine differences in 
these various metrics, but with the sample size present the beginnings of trends can be 
seen in every group.  
A weakness of the PSQI test is in its self-reporting nature. Many of the 
participants I talked to would follow up with me and talk to me about how they are 
feeling during the study. I noticed that many people commented that their sleep was far 
from ideal yet many reported low PSQI scores. I think one failure of the PSQI as a metric 
is that the primary participant population were college aged students. Many of whom do 
not face sleep issues such as “Cannot breathe comfortably” or “Cough or Snore Loudly” 
that are more common to an older population, or those with sleep apnea. If time 
permitted, it would be interesting to see statistical differences between groups for each 
question asked on each assessment. I also anticipated a larger placebo effect on self-
reported sleep seeing as the sham did administer a very brief pulse of stimulation to the 
sham participants, but it appears to have had very little effect on perceived sleep quality. 
The fact that the sham was active can also be a source of variability. Tyler et al. reported 
that stimulation of any sort can have tangible effects in subject populations, no matter 
how short, or shape of the waveform (Tyler,13). 
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Additionally, due to issues with the backend development several scores reported 
-1 for PSQI. -1 is not a valid value and at the time of writing this thesis the cause of the 
bug is unknown. An assumption was made that the -1 values were meant to be 0 for 
processing the data, should the bug be corrected the thesis will be corrected with new 
results. 
Fitbit 
 The Fitbit results are metrics that do not look like they will benefit from 
additional subjects. The primary aim of using the Fitbit was to objectively see if periods 
of wakefulness while asleep decreased and if total sleep duration became more normal 
420-480 minutes, 7-8 hours, of sleep per night is the recommended average sleep 
duration one should have. WASO and number of wakeups were key metrics in this study. 
Sham treatment was the only group that approached significance in any of its values, with 
light sleep having a significant pre/post difference. There is no way to measure sleep 
without the Fitbit but based on feedback from participants some found it more difficult to 
sleep while wearing the Fitbit, with one participant even claiming, “I almost quit the 
study because I hated the feeling of the Fitbit.”  
Lastly the Picard data collection service that was used to collect Fitbit seemed to 
randomly drop days from participants. Originally Picard would only remove data if the 
participant went to sleep after 3am or slept for less than 4 hours yet data was still missing 
even in subjects that confirmed they met these criteria. This is one of a few bugs that 
were encountered in the data collection process that may have impacted the results of this 
study. 
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Another factor to consider was that in the weeks of September and October in 
which these participants’ data were being collected, midterms were common. Two 
participants dropped from the study due to failing to sleep more than 4 hours for two 
nights. These two were filtered out but there could have been others that slept just long 
enough to still qualify for the study, while sacrificing sleep to prepare for midterm exams. 
used to collect Fitbit seemed to randomly drop days from participants. Originally Picard 
would only remove data if the participant went to sleep after 3am or slept for less than 4 
hours yet data was still missing even in subjects that confirmed they met these criteria. 
This is one of a few bugs that were encountered in the data collection process that may 
have impacted the results of this study. 
PANAS 
PANAS scores were one of the major metrics to indicate how mood was changing 
in the short term due to their daily measurement. One weakness in the PANAS analysis 
could have been averaging weekly values and comparing pre/post. Perhaps any change is 
being lost in the process of averaging the data due to some participants starting with 
fairly high scores in the 30’s and some starting in low twenties. A participant who starts 
high would not be expected to increase by much. An inclusion criterion could be added 
for participants that believe their sleep quality is affecting their mood but there is no way 
to check this. The point may also be moot since many people that signed up and 
completed this study would agree with this statement, only a small percentage of the 
participants (1-3 of 16) claimed to be sleeping enough before the study. 
PANAS scores were also recorded from participants at the same time audio 
recordings took place. A significant factor to consider is that some participants had 
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phones that were not compatible with Picard’s mobile recording, mostly older model 
iPhones. These participants tried many times to record and could not and would end up 
emailing me in frustration. This combined with several Android glitches that caused 
timers to misrepresent time or force participants to re-record 2 minutes of audio may have 
affected the PANAS scores that were recorded the same day. I did not ask participants in 
what order they submitted their audio and PANAS but it is very likely that a participant 
could have struggled to submit an audio file, which in turn caused them to fill out their 
PANAS form in frustration and skewed the results. 
Overall the PANAS does show some trending so perhaps the issue lays in sample 
size of the population. 
Beck Depression and Beck Anxiety Inventories 
There was one group, TENS group and Beck Anxiety Inventory, where there was 
a significant increase in the score. This contradicts the hypothesis of this study and results 
found in other publications. This could be due to several reasons including: midterm 
exams taking place during the study, participants feeling uncomfortable with the 
stimulator technology or sensation, or general fluctuations week to week since the 
increase was not statistically different from the sham group. The p-value for differences 
between sham and treatment was 0.738 which is not close to the target 0.05 which further 
suggests that the significance found for the group was likely an adverse effect. 
The Beck Anxiety inventory could have been affected by participants worrying 
about filling the form out. Many participants were unsure if their data was coming 
through and were anxious despite my telling them they were compliant. It is impossible 
to know what the scores on the surveys would show if filling them out didn’t add a 
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worrisome obligation, especially on a platform that may fail in other aspects such as the 
audio recording. 
The Beck Depression inventory was wholly uneventful with only the overall time 
group interaction showing significance but no significance upon further inspection 
between groups or within groups. 
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CHAPTER 5 
CONCLUSION 
Though the experiment yielded negative results there are several things that can 
be approved upon in future study design. As this thesis is being written there are more 
participants providing data to increases sample sizes. Given more time to test and develop 
the back end with Picard could reduce participant frustration with submitting their 
surveys and remove the possibility that participating in the study has an inherent 
influence on the measures. In follow-up studies a more diverse population should be 
chosen. Though exclusion criteria allow for a diverse group, college students should be 
considered for exclusion since their schedules are inherently fluctuating. The author is 
confident that this study has laid out preliminary groundwork for a future study that is 
more in-depth amongst a greater population of people. 
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IRB Number: HRP 503b 
Instructions and Notes: 
• Depending on the nature of what you are doing, some sections may not be applicable to your research. If so mark 
as “NA”.  
• When you write a protocol, keep an electronic copy. You will need to modify this copy when making changes. 
 
1 Protocol Title 
Effects of Transdermal Electrical Nerve Stimulation (TENS) on Sleep and Mood 
2 Background and Objectives 
Provide the scientific or scholarly background for, rationale for, and significance of the research based on the 
existing literature and how will it add to existing knowledge. 
• Describe the purpose, specific aims, or objectives. 
• State the hypotheses to be tested. 
• Describe the relevant prior experience and gaps in current knowledge. 
• Describe any relevant preliminary data. 
  39 
Transdermal electrical nerve stimulation (TENS) and pulsed transdermal electrical stimulation (pTES) devices are 
becoming increasingly popular therapeutic options due to their low invasiveness and low associated risk of use. For 
these same reasons, the FDA has approved many electrotherapy stimulation devices for use in the fields of pain relief, 
anxiety, depression, and sleep assistance. Many devices are even approved as recreational devices due to their low 
risk of adverse effects.  
 
Many studies done on the topic of nerve stimulation look for results in the long-term and specify through continued use 
of the devices that results are seen. An interesting question that should be addressed is whether these devices 
produce short-term impacts that can help users adjust sleep and behavior. A long-term study using a device called 
Thync showed that over a time of 1,386 days improvement in sleep was seen when the Thync device was used to 
stimulate the trigeminal sensory nuclear complex in 99 healthy individuals (Boasso et al., 2016). Thync has since 
restructured into a new device called Neuros created by Cerevast Medical Inc. It is with these devices that a follow up 
study should be conducted with similar experiments testing sleep quality, anxiety, and depression in the short-term. If 
improvements are seen and sustained in a short-term context then psychologically people can become less dependent 
on the devices and can treat them as an as needed therapy.  
 
Another interesting aspect of this study is the use of machine learning applications that determine mood based on 
subjects’ voices (Beyond Verbal, IBM Watson, etc.) and text (IBM Watson). This data will be analyzed and compared 
to gold standards such as Positive and Negative Affect Schedule, Beck Anxiety Inventory, and Beck Depression 
Inventory. Beyond Verbal is the only application thus far to be a clinically proven application for vocal biomarkers in 
depression. By comparing the other applications to gold standards, a small review of these methods can be compiled 
and commentary on the reliability of these applications in their current state can be made.  
 
The primary purpose of this study is to add knowledge on the short-term effects of these therapies. The treatments 
themselves have already been FDA approved and long-term effects have already shown clinical significance. Using 
the knowledge from this study, nerve stimulating devices such as Neuros may be able to recommend different therapy 
regiments for healthy individuals who need temporary assistance adjusting their sleep cycles or find themselves in a 
bout of depression. There is a lot to be learned from these minimal risk devices. 
 
References 
Ben-Menachem E (2001) Vagus Nerve Stimulation, Side Effects, and Long-Term Safety. Journal of Clinical 
Neurophysiology 18:415-418. 
Ben-Menachem E, Revesz D, Simon BJ, Silberstein S (2015) Surgically implanted and non-invasive vagus nerve 
stimulation: a review of efficacy, safety and tolerability. Eur J Neurol 22:1260-1268. 
Boasso AM, Mortimore H, Silva R, Aven L, Tyler WJ (2016) Transdermal electrical neuromodulation of the trigeminal 
sensory nuclear complex improves sleep quality and mood. bioRxiv. 
Merrill DR, Bikson M, Jefferys JG (2005) Electrical stimulation of excitable tissue: design of efficacious and safe 
protocols. J Neurosci Methods 141:171-198. 
 
3 Data Use 
Describe how the data will be used.  Examples include: 
• Dissertation, Thesis, Undergraduate honors 
project 
• Publication/journal article, 
conferences/presentations 
• Results released to agency or organization 
 
 
• Results released to participants/parents 
• Results released to employer or school 
• Other (describe) 
The data collected in this study will primarily be used as a master’s thesis by Ceasar Udave in the School of Biological 
and Health Systems Engineering Biomedical Engineering master’s program. Upon completion of thesis defense, the 
thesis will be submitted for publication in November 2018 to peer reviewed journals related to engineering, 
neuromodulation, and neurosciences. 
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4 Inclusion and Exclusion Criteria 
Describe the inclusion and the exclusion criteria for the study. 
Describe how individuals will be screened for eligibility. 
Indicate specifically whether you will target or exclude each of the following special populations:  
• Minors (individuals who are under the age of 18) 
• Adults who are unable to consent 
• Pregnant women 
• Prisoners 
• Native Americans 
• Undocumented individuals 
Inclusion criteria 
• Only adult males and females aged 18-65 will be enrolled. 
• All adults will be able to give consent. 
• Be full-time worker, full-time student, OR the combination of a part-time student and worker discussed in the 
phone interview. 
• All eligible study participants will be screened for eligibility using an online questionnaire through REDCap 
software or telephone interview prior to scheduling, consent, and enrollment or exclusion. 
 
Exclusion criteria 
• No daily access to a PC desktop/laptop or smartphone with Internet access.  
• Currently undergoing treatment or medication for neurological or psychological disorder, including addiction 
• Has a medical implant (such as a pacemaker, cochlear implant, brain stimulation device) 
• History of migraines or frequent headaches 
• History of panic attack or acute anxiety disorder 
• Fainting (vaso-vagal syncope or neurocardiogenic syncope) 
• Raynaud's disease 
• Tempomandibular joint (TMJ) disorder or other facial neuropathy 
• History of concussions or brain injury 
• History of significant face/head injury or if you have cranial or facial metal plate or screw implants 
• History of hospitalization for neurological or psychological disorder 
• Recent hospitalization for surgery/illness 
• Vision or hearing that is uncorrectable (corrected vision or hearing is okay) 
• Pregnant 
• Recent drug or alcohol treatment 
• High blood pressure, heart disease, or diabetes 
• Diagnosed with sleep disorder  
• Taking prescription medication for sleep 
5 Number of Participants 
Indicate the total number of participants to be recruited and enrolled 
• Provide a rationale for the proposed enrollment number 
• What percentage of screened individuals will likely qualify for the study?  
For this study 50 total participants will be the target number. According to power analysis run in RStudio a minimum 
participant number of 16 is necessary to show an effect of approximately 10% with 90% confidence. We anticipate that 
100 people will need to be screened to meet the exclusion criteria. Subjects will be enrolled in the study 10 participants 
at a time to ensure all participants have all required materials. 
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6 Recruitment Methods 
• Describe when, where, and how potential participants will be identified and recruited. 
• Describe materials that will be used to recruit participants. (Attach copies of these documents with the 
application.) 
• Does any member have a dual role with the study population? 
Participants will be recruited mostly through word of mouth and by email to a registry of students who have previously 
participated in the lab’s studies. Flyers for general advertisement and electronic advertisement have been created and 
attached to this IRB along with a sample email for recruiting from previous lab participants. 
 
7 Study Timelines 
Describe: 
• The duration of an individual participant’s participation in the study. 
• The duration anticipated to enroll all study participants. 
• The estimated date for the investigators to complete this study (up to and including primary analyses). 
The primary planning for the study occurred from January to May. The IRB submission/revision process is scheduled 
June to August. S Upon IRB approval (August 2018) subjects will be recruited, informed, and data collection will begin. 
After 2 weeks of data collection the data will be analyzed and processed over the following 6 weeks. November 2018 is 
the goal for a competed thesis and December 2018 will be the conclusion of the study with a thesis defense to a 
committee of representatives from the School of Biological and Health Systems Engineering. Upon completion of 
thesis defense, the thesis will be submitted for publication in  2018/2019 peer reviewed journals related to engineering, 
neuromodulation, and neurosciences. 
 
8 Procedures Involved 
Describe and explain the study design. Provide a description of all research procedures being performed and 
when they are performed. Describe procedures including: 
• The documents/ measures / devices/ records /sampling that will be used to collect data about 
participants. (Attach all surveys, scripts, and data collection forms.) 
• What data will be collected including long-term follow-up?  
• All drugs and medical devices used in the research and the purpose of their use, and their regulatory 
approval status. 
• Describe the available compensation (monetary or credit that will be provided to research participants). 
• Describe any costs that participants may be responsible for because of participation in the research. 
  42 
The primary methods of data collection will be through survey. The Positive Affect and Negative Affect Schedule 
(PANAS) Questionnaire will be used daily to record ratings on subject daily moods. A daily sleep diary survey will also 
be used daily to allow subjects to self-report sleep quality daily over the course of the study. In conjunction with the 
sleep diary a Fitbit will be worn by the participants for most of the day (excluding shower, swimming, etc) to collect data 
on sleep quality, and heart rate. Weekly, subjects will take  the Beck Anxiety Inventory, and the Beck Depression 
Inventory to determine if their depression and anxiety scores have reduced with use of trigeminal nerve stimulation. 
Daily, the Pittsburgh Sleep Quality Assessment and Fitbit actigraphy will be used to assess sleep quality data. All 
subjects will be trained on all procedures prior to study start date. A resource list of emergency contacts will be 
provided to all subjects in the event that any subject feels depressed or believes they have suicidal tendencies. 
Following the end of the treatment period research participants will be asked to complete a computerized questionnaire 
asking them to rate their experience with the study device/treatment.  
 
The stimulator that will be used is an over the counter pulsed transdermal electrical stimulation (pTES) unit called 
Neuros created by Cerevast Medical Inc. The maximum current used by the device is up to 4mA which is approx. 
1/10th that of the highest allowable current for safety in humans approved by the FDA. Many over the counter TENS 
units operate at a higher current and have proven to be safe for use with humans. The stimulator will be used for the 
recommended 15 minutes daily before sleep and subjects will be taught how to properly use the device. All subject 
questions and concerns will be addressed before the device is provided for use.  
 
Transcutaneous electrical stimulation of peripheral nerves including cranial nerves like the trigeminal and vagal nerve 
is a noninvasive procedure that involves minimal risk by transmitting weak electrical impulses across the skin to 
underlying nerves using transdermal electrodes. Transcutaneous electrical nerve stimulation (TENS) using weak 
pulsed currents to noninvasively stimulate nerves have a long safety record dating back decades. The basic procedure 
involves the positioning and placement of standard transcutaneous neurostimulation electrodes with hydrogel. 
Targeting of the trigeminal and cervical nerves will be achieved using previously described procedures where 
electrodes are placed at the base of the neck and the side of the forehead or face (Tyler et al., 2015). 
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Over-the-counter and cosmetic TENS devices, such as Rejuvenique Face Toning Mask (RJV10), NuFace Trinity, 
Strivectin Facial Toner, IcyHot Smart Relief, Aleve Direct Therapy and numerous others have maximum current 
outputs up to 100 mA into a 500-ohm load with peak voltages up to 80 V. Other transdermal electrical stimulators like 
electrical muscle stimulators (EMS), such as the Compex Sport Elite or neuromuscular electrical stimulators (NMES) 
used for lifestyle, recreational, or cosmetic applications have current outputs that exceed 120 mA with peak voltages 
up to 200 V. 
 
Pulse widths on peripheral nerve stimulators can range from 3 microseconds to several milliseconds depending on a 
given stimulus protocol and intended use. Prescription, over-the-counter, and direct-to-consumer peripheral nerve 
stimulation devices generate stimulus waveforms that span a diverse range of pulse frequencies from 1 Hz to 20 kHz. 
The low-risk designation of TENS, EMS, NMES, electroacupuncture, and other devices used for medical, lifestyle, or 
cosmetic applications has led to the FDA-exemption of similar, consumer neurostimulation products intended for 
general health or wellness purposes.  
 
All pulse parameters used for transcutaneous nerve stimulation of the trigeminal and cervical nerves will be within safe 
ranges referenced above. Pulsed stimuli used for TENS will have variable intensities with peak amplitudes < 20 mA at 
frequencies ranging from 10 Hz to 5 kHz. As recommended for safe application of TENS the current density will remain 
less than 2 mA/cm2. TENS electrodes will be made of biocompatible polymers, such as conductive silicon or carbon 
fiber and have an insulating layer comprised of a hydrogel. Electrodes will be standard to the Neuros device from 
Cerevast Medical Inc.. Electrodes will be positioned to target branches of the trigeminal and cervical nerves as 
previously described (Tyler, 2015). Users will be able to exert control over the stimulus amplitude (TENS intensity) 
such that they can maintain a 
comfortable level of stimulation throughout the experimental protocol. Each participant will be exposed to no more than 
20 minutes of stimulation per day which is within the recommended range of over-the-counter TENS devices. 
 
Lastly a software combination of Beyond Verbal API and IBM Watson Text to Speech API will be used to assess daily 
mood by asking the subject how they felt that day. The data collected by these APIs will be deidentified and stored in a 
private cloud maintained by the Tyler Lab. All data will be de-identified in a cloud storage service called Picard.io. 
Picard is a HIPAA compliant data storage and collection platform. 
 
Research participants will be compensated $50 a week for approximately 10 hours of commitment. The maximum 
compensation is $100 for the completion of the two-week study. The subjects will face no expenses of their own as 
each will be loaned the materials that are needed to conduct the study. The compensation shall be paid at the end of 
the two week period given that the subjects are not removed from the study for compliance issues including: not filling 
out required forms, skipping use Cerevast Neuros devices, etc. Participant funding is supported by ASU internal 
Weartech program funds. Participants will be compensated after all study related devices are returned and the ASU 
Petty Cash Fund Expenditure Register Form is signed. Participants expected to earn more than $600 in a calendar 
year for human subjects research at ASU will be asked to completed applicable tax forms (e.g. ASU Substitute W-9 or 
W-8BEN) in compliance with ASU FIN 421-05.   
 
9 Withdrawal of Participants 
Describe anticipated circumstances under which participants will be withdrawn from the research without their 
consent. 
Describe procedures that will be followed when participants withdraw from the research, including partial 
withdrawal from procedures with continued data collection. 
Participants are free to withdraw from the study at any time. Since only able-bodied participants will be accepted there 
are no circumstances under which we would expect a participant to withdraw. If the participant does withdraw during 
data collection, then we may still use the data collected from the participant, with the participant’s verbal consent. 
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10 Risks to Participants 
List the reasonably foreseeable risks, discomforts, hazards, or inconveniences to the 
participants related the participants’ participation in the research. Include as may be 
useful for the IRB’s consideration, the probability, magnitude, duration, and reversibility 
of the risks. Consider physical, psychological, social, legal, and economic risks. 
Reference this information when appropriate. 
• If applicable, indicate which procedures may have risks to an embryo or fetus 
should the participant be or become pregnant. 
• If applicable, describe risks to others who are not subjects. 
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TENS is considered a low risk procedure and is routinely used in research, for medical indications, and in over-the-
counter or direct-to-consumer applications. With respect to the safety, there exists a wealth of primary data and clinical 
endpoints demonstrating broad safety margins for electrical stimulation of peripheral nerves including cranial nerves 
like the vagus and trigeminal nerves (McCreery et al., 1990, Ben-Menachem, 2001, Merrill et al., 2005, Ben-Menachem 
et al., 2015). These noninvasive cranial nerve TENS approaches are also used in direct-to-consumer devices intended 
to relieve stress or promote relaxation. This latter use of TENS is what this study will primarily use. 
 
Transcutaneous electrical stimulation of peripheral nerves including cranial nerves like the trigeminal and vagal nerves 
is a noninvasive procedure that involves minimal risk by transmitting weak electrical impulses across the skin to 
underlying nerves using transdermal electrodes. Transcutaneous electrical nerve stimulation (TENS) using weak 
pulsed currents to noninvasively stimulate nerves have a long safety record dating back decades as previously 
described. The basic procedure involves the positioning and placement of standard transcutaneous neurostimulation 
electrodes having a hydrogel. Targeting of the trigeminal and cervical nerves will be achieved using previously 
described procedures where electrodes are placed at the base of the neck and the side of the forehead or face (Tyler 
et al., 2015). 
 
There have been no known severe adverse events associated with the use of TENS. However, there is a low-risk for 
some minor side-effects or adverse reactions. Subjects with sensitive skin may experience skin irritation in the area 
where electrodes are applied. Some subjects may experience a headache and other painful sensations during or 
following the application of electrical stimulation. Some subjects may experience a sensation of hearing ringing tones 
after electrical stimulation. 
 
Skin Irritation Risk 
Minor skin irritation can occur if electrodes are placed over broken skin or wounds. We will avoid placing electrodes 
over these areas. Moreover, we will inspect the skin prior to electrode placement to further reduce the potential for 
minor irritation. Mild redness has been reported at the site of electrode placement, but this is an acute effect of 
vasodilation as opposed to inflammation and thus does not indicate damage. 
 
Skin Discomfort Risk 
Skin sensations during TENS are transient, most prominent at the onset and offset of stimulation and do not persist 
beyond the timeframe of stimulation. With proper use the most common sensation from TENS is tingling at the 
electrode site, which is not uncomfortable or painful. However, depending on the amplitude of the current, 
uncomfortable sensations may occur, including a sensation of pain or heat. To minimize these sensations, we are 
using electrodes that have been specially designed to distribute current across the electrode-skin interface. In addition 
subjects will be able to decrease the current amplitude or abort the stimulation paradigm if they become uncomfortable 
at any time. 
 
Headache 
A rare side effect of TENS and transdermal cranial nerve modulation is the occurrence of a mild headache. This occurs 
in less than about 10% of subjects at incidence rates similar to sham procedures during both acute and repeated use 
procedures. Mild headaches typically resolve within a couple hours with no further complications. If a subject 
experiences a headache or discomfort, they may discontinue use at any time. 
 
There are no other known risks associated with this study. Participation is completely voluntary and participants are 
free to ask questions, ask for a break or withdraw from the study without penalty. A signed copy of the consent form 
will be given to each participant for each session. 
 
11 Potential Benefits to Participants 
Realistically describe the potential benefits that individual subjects may experience 
from taking part in the research. Include the probability, magnitude, and duration of the 
potential benefits. Indicate if there is no direct benefit. Do not include compensation or 
benefits to society or others. 
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By taking an active role in this study participants will be able to see their own changes in mood and sleep based on 
their Fitbit readings and feedback from their sleep journals.  
12 Setting 
Describe the sites or locations where your research team will conduct the research. 
• Identify where research procedures will be performed. 
• For research conducted outside of the ASU  describe: 
o Site-specific regulations or customs affecting the research. 
o Local scientific and ethical review structures in place. 
There will be an initial training session at ASU where the participants will be taught how to access the surveys, how to 
use the Neuros device, and baseline personality profiles will be taken. The remainder of the data will be collected 
through picard.io and REDCap software remotely from the participants’ location. Each participant will be free to 
conduct the protocols at home since they are simple. Email reminders will be used to make sure the participants are 
recording necessary data when needed.  
 
13 Multi-Site Research 
If this is a multi-site study where you are the lead investigator, describe the processes you will use to ensure 
communication among sites, such as: 
• Each site has the most current version of the protocol, consent document, and HIPAA authorization. 
• Required approvals have been obtained at each site (including approval by the site’s IRB of record). 
• Describe processes you will use to communicate with participating sites. 
• Participating sites will safeguard data as required by local information security policies. 
• Local site investigators conduct the study appropriately. 
NA 
14 Resources Available 
Describe the qualifications (e.g., training, experience, oversight) of you and your staff as required to perform your 
roles. When applicable describe knowledge of the local study sites, culture, and society. Provide enough 
information to convince the IRB that you have qualified staff for the proposed research. 
Describe other resources available to conduct the research: For example, as appropriate: 
• Describe your facilities. 
• Describe the availability of medical or psychological resources that participants might need as a result of 
any anticipated consequences of the human research. 
• Describe your process to ensure that all persons assisting with the research are adequately informed 
about the protocol, the research procedures, and their duties and functions. 
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The research will be conducted under the supervision of Dr. William Tyler. The PI has more than ten years’ experience 
investigating and developing noninvasive neuromodulation methods, devices, and systems. These investigations 
include the development of methods for optimizing transcranial magnetic stimulation and the development of 
transcranial focused ultrasound for neuromodulation. In addition, the PI has had independent experience in leading a 
company from product conceptualization to launching a direct-to-consumer neuromodulation device (transdermal 
electrical neuromodulation device), which was exempted from regulatory enforcement by the FDA under a 513.g 
precedent decision. In addition to industry efforts and academic research, the PI is an authority and published expert 
on the safety of noninvasive neuromodulation devices including forthcoming industry guidelines for direct-to-consumer 
devices. The PI also has experience training undergraduate students, graduate students, 
postdoctoral scholars, professors, and other users on a variety of noninvasive neuromodulation methods for diverse 
applications.  
 
The Tyler Laboratory is equipped with the necessary materials such as Neuros devices, mood inventories, Fitbits, and 
sleep inventories for subjects to take with them. The Tyler Lab will train subjects to use all materials safely and 
comfortably prior to the beginning of the study via in person workshops. 
 
Graduate students and postdoctoral fellows to be involved in the research will provide required CITI documentation 
and will be trained on specific laboratory procedures before being added to the IRB protocol. Research training records 
will be maintained in the laboratory with other safety 
training procedures. 
 
Attached to the consent form that participants take with them will be a list of mental health services in the event that a 
participant feels they have significant mood changes or disturbances.  
 
15 Prior Approvals 
Describe any approvals that will be obtained prior to commencing the research. (E.g., school, external site, 
funding agency, laboratory, radiation safety, or biosafety approval.) 
The local ASU IRB is the only approval that is needed for this research. 
16 Data Management and Confidentiality 
Describe the data analysis plan, including procedures for statistical analysis. 
Describe the steps that will be taken to secure the data during storage, use, and transmission.  
• Training, authorization of access, password protection, encryption, physical controls, certificates of 
confidentiality, and separation of identifiers and data  
Describe how data and any specimens will be handled: 
• What personal identifiers will be included in that data or associated with the specimens? 
• Where and how data or specimens will be stored? 
• How long the data or specimens will be stored? 
• Who will have access to the data or specimens? 
• Who is responsible for receipt or transmission of the data or specimens? 
• How will data and specimens be transported? 
• If data or specimens will be banked for future use, describe where the specimens will be stored, how long 
they will be stored, how the specimens will be accessed, and who will have access to the specimens. 
• Describe the procedures to release data or specimens, including: the process to request a release, 
approvals required for release, who can obtain data or specimens, and the data to be provided with 
specimens. 
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A master contact list containing participant names, email addresses, and phone numbers will be stored in a locked file 
cabinet separate from the consents, questionnaires, physiological, and audio data. Consents forms will also be stored 
in a locked file cabinet separate from the master contact list. Participants will be assigned a Study ID (e.g. P1, P2, 
P3...) and User Login ID (e.g. weartech1@asu.edu, weartech2@asu.edu...) that will be used to create/track audio 
recordings, Fitbit tracking accounts, and Neuros training accounts. Data and audio files will be exported without any 
participant identifiers and stored in computer memory and digital storage backup drives for up to 10 years. The 
computer memory will be accessible via secure login only to study personnel named in this document; data and audio 
will remain secured on Arizona State University property in the Tyler Laboratory PEBE rooms 158C, 150, and 220 
Digitally stored data (on the computer or in backup drives) will not contain any identifiable information on the 
participant.  
 
17 Safety Monitoring 
This is required when research involves more than Minimal Risk to participants. The plan might include 
establishing a data monitoring committee and a plan for reporting data monitoring committee findings to the IRB 
and the sponsor.  Describe: 
• The plan to periodically evaluate the data collected regarding both harms and benefits to determine 
whether participants remain safe. 
• What data are reviewed, including safety data, untoward events, and efficacy data? 
• How the safety information will be collected (e.g., with case report forms, at study visits, by telephone 
calls with participants). 
• Who will review the data? 
This study has been designated to have a Minimal Risk Level. There are no other known risks associated with this 
study. Participation is completely voluntary and participants are free to ask questions, ask for a break or withdraw from 
the study without penalty. We will hold weekly laboratory meetings with the research personnel involved in this 
research to discuss any adverse reactions, which may have occurred during the study. We will collect some 
questionnaire information (REDCap, Picard) at the end of each study treatment session asking participants to describe 
any adverse reactions. Safety will be continuously tracked and monitored throughout the study by the local research 
personnel affiliated with the study. An emergency resource list shall be provided to every subject in case of an event 
that a subject feels depressed or feels that they may have suicidal tendencies based on their answers to the Beck 
Depression Inventory. 
 
 
18 Consent Process 
Describe the process and procedures process you will use to obtain consent. Include a description of: 
• Who will be responsible for consenting participants? 
• Where will the consent process take place? 
• How will consent be obtained?  
• If participants who do not speak English will be enrolled, describe the process to ensure that the oral 
and/or written information provided to those participants will be in that language. Indicate the language 
that will be used by those obtaining consent.  Translated consent forms should be submitted after the 
English is approved. 
Before the study officially begins a small workshop will be held with the participants. Participants will be provided with 
the study information, study rationale, risks, potential benefits, and the role of the IRB. All participants will be asked to 
complete the Informed Consent form in writing; the consent form will be dated and countersigned by the PI, and one 
copy will be provided to the participant (Consent form is attached). The participant may withdraw from the study at any 
time. All participants will be English speaking and all will be adults capable of giving informed consent. 
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19 Investigational New Drug or Devices 
If the drug is investigational (has an IND) or the device has an IDE or a claim of abbreviated IDE (non-significant 
risk device), include the following information: 
• Identify the hold of the IND/IDE/Abbreviated IDE. 
• Explain procedures followed to comply with FDA sponsor requirements for the following: 
 
 Applicable to: 
FDA Regulation IND Studies IDE studies 
Abbreviated IDE 
studi
es 
21 CFR 11 X X  
21 CFR 54 X X  
21 CFR 210 X   
21 CFR 211 X   
21 CFR 312 X   
21 CFR 812  X X 
21 CFR 820  X  
 
NA 
20 CITI 
Provide the date that the members of the research team have taken the CITI training for human participants.  This 
training must be taken within the last 4 years. Additional information can be found at: 
http://researchintegrity.asu.edu/training/humans 
 
William Tyler 
Sarah Wyckoff 
Ceasar Udave 
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Recruitment Email 
Hello! 
 
If you are receiving this email it is because you expressed interest in taking part in 
future Tyler Lab studies. The Tyler Lab will be conducting a new study on 
neuromodulation and its effects on sleep and mood. We are working on validating 
different software packages to detect mood and looking to study short term trends in 
sleep and mood with normal use of transdermal neurostimulation. 
 
Details: 
Must be 18-65 to participate. 
Participation is voluntary 
Must pass a prescreening phone call or online survey. (Less than 5 minutes). 
 
Study will last approximately 2 weeks with the participant involved no more than 10 
hours a week. 
 
Participation will involve: 
-Neurostimulation using approved over the counter pulsed transdermal electrical 
stimulation device for trigeminal nerve stimulation. 
-Vocal recordings for use with software packages. 
-Filling out mood and depression inventories. 
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-Keeping a sleep diary. 
-Wearing a Fitbit to record sleep activity.  
 
Participants will be given $125 per week of participation. 
 
If interested please email us back at study1@tylerlab.com with the subject “Sleep Study”. 
 
Thank you for your time, 
Ceasar Udave 
 
Reminder Email 
 
Hello Study Participant! 
This is a friendly reminder that all surveys need to be completed before midnight. Neuros 
stimulation must be complete before you go to bed and wear your Fitbit while you sleep. 
Login with your Weartech credentials to see what still needs to be completed today at: 
https://weartech.picard.io 
Thank you from the Tyler Lab Staff! 
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Consent Form 
 
SUBJECT CONSENT FORM 
 
Examination of Pulsed Transdermal Electrical 
Stimulation (pTES) and its Effects on Sleep and 
Mood 
 
School of Biological and Health Systems Engineering: Arizona State 
University 
 
 
Introduction: 
 
The purpose of this form is to provide you (a prospective research participant) with 
pertinent information that may affect your decision to participate in this research and to 
record consent of those who agree to be involved. 
 
Principle Investigator & Research Associates: 
 
William Tyler, Ph.D., (PI, Associate Professor, School of Biological and Health Systems 
Engineering) 
Ceasar Udave (graduate student, SBHSE) 
Sarah Wyckoff, Ph.D. (research assistant professor). 
 
Study Purpose: 
 
The purpose of this study is twofold. Primarily, the data collected will be used to 
determine if regular use of pulsed transdermal electrical stimulation (pTES) has 
beneficial effects to the sleep of users in a short-term time frame using Fitibit, and the 
Pittsburgh Sleep Quality Assessment (PSQI). Secondly, mood data collected from gold 
standard questionnaires such as the Positive Affinity Negative Affect Schedule 
(PANAS), Depression Anxiety and Stress Scale (DASS21), Beck Anxiety Inventory, and 
Beck Depression Inventory will be compared against software packages Beyond Verbal, 
and IBM Watson to determine the validity of these software packages in assessing mood. 
 
Description of Research Study: 
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You will be one of approximately 20 able-bodied healthy individuals to be asked to 
participate in this project. You will be asked to perform the following procedures at home 
with training and continued support from the research faculty. 
 
Testing: 
○You will be expected to wear a Fitbit for the duration of the study. Excluding during 
showers. 
 
○Once daily you will use a Cerevast Neuros pTES units. Training on how to use the 
device, settings available, best practices, and other information will be provided. 
 
Description of Research Study (cont.): 
 
○Once daily you will take the Positive and Negative Affect Schedule. 
 
○Once weekly you will take the Pittsburgh Sleep Quality Assessment  
  
○Once daily you will make an audio recording responding to a prompt 
 
○Once weekly you will take the Beck Depression Inventory 
 
○Once weekly you will take the Beck Anxiety Inventory 
 
The inventories, schedules, assessments, and scales described above are simple 
questionnaires that will be filled out through an online service called Picard.io. Picard.io 
is a HIPAA compliant data collection service that guarantees confidentiality and will 
provide each subject with their own access portal. 
 
One mandatory training session will be held before the study begins. At this training 
session subjects will be taught how to access their Picard.io accounts, be assigned their 
equipment, walked through each of the questionnaires, taught how to use their Fitbits, 
taught how to use their Cerevast Neuros devices, and taught what to expect in an average 
day of the study by completing baseline surveys. The estimated time of commitment for 
each subject will be approx. 10 hours/ week. 
 
Risks: 
This study has been designated to have a Minimal Risk Level. There have been no 
known severe adverse events associated with the use of TENS. There is a low-risk for 
some minor side-effects or adverse reactions however. Subjects with sensitive skin 
may experience skin irritation in the area where electrodes are applied. Some subjects 
may experience a headache and other painful sensations during or following the 
application of electrical stimulation. Some subjects may experience a sensation of 
hearing ringing tones after electrical stimulation. 
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Skin Irritation Risk 
Minor skin irritation can occur if electrodes are placed over broken skin or 
wounds. We will avoid placing electrodes over these areas. Moreover, we will 
inspect the skin prior to electrode placement to further reduce the potential for 
minor irritation. Mild redness has been reported at the site of electrode 
placement, but this is an acute effect of vasodilation as opposed to 
inflammation and thus does not indicate damage. 
 
 
 
 
Skin Discomfort Risk 
Skin sensations during TENS are transient, most prominent at the onset and 
offset of stimulation and do not persist beyond the timeframe of stimulation. 
With proper use the most common sensation from TENS is tingling at the 
electrode site, which is not uncomfortable or painful. However depending on 
the amplitude of the current, uncomfortable sensations may occur, including a 
sensation of pain or heat. To minimize these sensations, we are using electrodes 
that have been specially designed to distribute current across the electrode-skin 
interface. In addition, subjects will be able to decrease the current amplitude or 
abort the stimulation paradigm if they become uncomfortable at any time. 
 
Headache 
A rare side effect of TENS and transdermal cranial nerve modulation is the 
occurrence of a mild headache. This occurs in less than about 10% of subjects 
at incidence rates similar to sham procedures during both acute and repeated 
use procedures. Mild headaches typically resolve within a couple hours with no 
further complications. If a subject experiences a headache or discomfort, they 
may continue use at any time. 
 
Inclusion Criteria: 
 
○Healthy males or females aged 18-65. 
○Full time workers or students (or part time combination approved by investigators) with 
regular sleep schedules. 
 
Exclusion Criteria: 
Please check each box acknowledging that you do NOT have this condition or 
exclusion criteria. 
 Currently undergoing treatment or medication for neurological or psychological 
disorder, including addiction 
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 Has a medical implant (such as a pacemaker, cochlear implant, brain stimulation 
device) 
 History of migraines or frequent headaches 
 History of panic attack or acute anxiety disorder 
 Fainting (vaso-vagal syncope or neurocardiogenic syncope) 
 Raynaud's disease 
 Tempromandibular joint (TMJ) disorder or other facial neuropathy 
 History of concussions or brain injury 
 History of significant face/head injury or if you have cranial or facial metal plate 
or screw implants 
 History of hospitalization for neurological or psychological disorder 
 Recent hospitalization for surgery/illness 
 Vision or hearing that is uncorrectable (corrected vision or hearing is okay) 
 Pregnant 
 Recent drug or alcohol treatment 
 High blood pressure, heart disease, or diabetes 
 Diagnosed with sleep disorder  
 Taking prescription medication for sleep 
Benefits: 
 
Using the Fitbit data and various mood assessments given in the study, participants will 
gain a better understanding of their sleep schedules, moods on a weekly and daily basis, 
and learn awareness of their own health. The data collected in this study will help the 
investigators understand how an emerging technology can affect the patient population 
who may use these devices. 
New Information: 
If the researchers find new information during the study that would reasonably change 
your decision about participating, then they will provide this information to you. 
 
Confidentiality: 
 
Every effort will be made to maintain the confidentiality of your participation in this 
project. Each subject’s name will be paired with a code number by the principal 
investigator. This code number will appear on all written materials. The list pairing the 
subject’s name to the assigned code number will be kept separate from all research 
materials and will be available only to the principal investigator. Confidentiality will 
be maintained within legal limits. 
 
Withdrawal: 
You may choose to withdraw from the study at any time. If you do withdraw, then any 
data collected from you prior to your withdrawal will only be used under your verbal 
consent. 
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Compensation: 
 
Compensation will be $125 per completed week of study requirements. Should any 
subject fail to comply with the parameters of the study their compensation will be 
forfeited, and they will be asked to leave the study.  
 
Compensation for Illness and Injury: 
 
If you consent to participate in the study, then your consent does not waive any of your 
legal rights. However, no funds have been set aside to compensate you in the event of an 
injury. 
 
Voluntary Consent:  
 
1. I understand that informed consent is required of all persons participating in this 
project. 
 
2. All procedures have been explained to me and all my questions have been 
answered to my satisfaction. 
 
3.  Any risks and/or discomforts have been explained to me. 
 
4. Any benefits have been explained to me. 
 
5. I understand that any questions that I have concerning the research study or my 
participation in the research study, before or after my consent, will be answered 
by William Tyler, Ph.D. or research associates, Tyler Laboratory, School of 
Biological and Health Systems Engineering, PEBE 158C, at 480-965-9270. 
  
I also understand that if I have questions about my rights as a subject/participant 
in this research, or if I feel I have been placed at risk, I can contact the Chair of 
the Human Subjects Institutional Review Board, through the ASU Research 
Compliance Office, at 480- 965-6788 
 
6. I have been told that I may refuse to participate or to stop my participation in this 
project at any time before or during the project. I may also refuse to answer any 
question. 
 
7. All information that is obtained in connection with this project and that can be 
identified with me will remain confidential as far as possible within legal limits. 
Information gained from this study that can be identified with me may be released 
to no one other than the principal investigator. The results may be published in 
scientific journals, professional publications, or educational presentations without 
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identifying me by name. 
 
8. This form explains the nature, demands, benefits and any risk of the project. By 
signing this form, I agree knowingly to assume any risks involved. My 
participation is voluntary. I may choose not to participate or to withdraw my 
consent and discontinue participation at any time without penalty or loss of 
benefit. In signing this form, I am not waiving any legal claims, rights or 
remedies. A copy of this consent form will be offered to me. 
 
 My signature means that I agree to participate in the study. 
 
 
 
 
 
Subject’s Signature Printed Name Date 
 
 
 
 
 
 
 
 
“I certify that I have explained to the above individual the nature and purpose, the 
potential benefits and possible risks associated with participation in this research study, 
have answered any questions that have been raised, and have witnessed the above 
signature. These elements of Informed Consent conform to the Assurance given by 
Arizona State University to the Office for Research Integrity and Assurance to protect 
the rights of human subjects. I have provided (offered) the subject/participant a copy of 
this signed consent document” 
 
Signature of Investigator   Date   
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Sleep Study Ad Electronic and Flyer 
 
Study on 
Sleep and Mood Improvement 
at Arizona State University 
We are investigating noninvasive neuromodulation methods for the 
improvement of sleep schedule and quality, as well as improvement in mood 
in an acute time frame. 
 
The details: 
Must be 18-65 years of age to participate in study. 
 
Must be available for a 2-week time period in June/July. 
 
Must be a full-time student/ Have full time employment during study. 
 
Participation is voluntary. 
 
If interested please email 
 
study1@tylerlab.com with the subject line “Sleep Study” 
to request a pre-screening telephone interview/online survey, which should last 
less than 5 minutes. 
 
Study period will last approximately 2 weeks. 
 
 
Volunteer participation will involve one laboratory visit 
training and include: 
 
-Use of a Fitbit to monitor sleep quality 
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-Transcutaneous electrical nerve stimulation of trigeminal/cervical nerves with 
over the counter therapy device. 
-Recording of verbal responses to prompts. 
-Computerized questionnaires used to evaluate mood. 
-Self-administered questionnaires, nerve stimulation, and Fitbit recordings in 
the comfort of your own home. 
 
 
Participants will be compensated with $125 per week of participation. 
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Counseling Services Information 
 
Counseling Service Providers 
 
 
ASU Counseling Services staff is available for walk-ins, appointments or to provide 
consultation anytime between 8 a.m. – 5 p.m. Monday thru Friday. Call (480) 965-6146 to be 
connected to any of our four campus locations.  
 
Downtown Phoenix Campus 
Phone: 602-496-1155 
Street Address 
Historic Post Office Building 
522 N. Central Avenue, Suite 208 
Phoenix, AZ 85004 
 
Tempe Campus 
Phone: 480-965-6146 
Street Address 
Student Services Bldg, Rm 334 
1151 S. Forest Ave. 
Tempe, AZ 85287 
 
Polytechnic Campus 
Phone: 480-727-1255 
Street Address 
Academic Center, Suite 92 
5988 S. Backus Mall 
Mesa, AZ 85212 
 
West Campus 
Phone:602-543-8125 
Street Address 
University Center Building, Room 221 
4701 West Thunderbird Road 
Glendale, AZ 85306 
If a crisis occurs outside of business hours call EMPACT’s 24-hour ASU-dedicated crisis hotline: 
480-921-1006 
 
 
Student Advocacy and Assistance in the Dean of Students office guides students in resolving 
educational, personal and other difficulties by linking students with appropriate university and 
community resources. Call 8 a.m. – 5 p.m. Monday thru Friday. 
 
Downtown Phoenix Campus 
602-496-0670 
Polytechnic Campus 
480-727-5269 
Tempe Campus 
480-965-6547 
West Campus 
602-543-8152 
 
Maricopa Crisis Line You can call for help with a behavioral health crisis 24 hours a day, 7 
days a week. It’s available for anyone at any time. Crisis Response Network, Inc. (CRN) 
operates the Crisis Line. Their experienced, professionally trained Crisis Specialists are ready to 
respond to whatever crisis an individual is facing. They provide immediate and confidential help. 
If your crisis can’t be solved over the phone, CRN may dispatch mobile clinicians to meet you 
where you are.  
 
Phone: 602-222-9444  
1-800-631-1314 (toll free)  
www.crisisnetwork.org 
 
National Suicide Prevention Hotline 
Phone:1-800-273-8255 
 
For emergency situations, call (9-1-1).  
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Sleep Surveys 
 
[All surveys were done online through a service called Picard by Trialomics. Please 
contact the author to obtain copies of the surveys used. All surveys can be found online.] 
  62 
BIOGRAPHICAL SKETCH 
 I completed my bachelor’s degree here at Arizona State University in Biomedical 
Engineering. I am currently a 4 + 1 MS thesis student working under Dr. William Tyler. 
My research was inspired by my brief internship period at NASA, where I learned one of 
the main issues astronauts still face is a sleep deficit, due to lack of gravity, prolonged 
days, and abnormal day night cycles. The Tyler Lab is interested to see if transdermal 
electrical nerve stimulation (TENS) to the trigeminal nerve can help correct sleep patterns 
and improve mood in the short term. Following graduation, I plan on working in the 
biomedical industry to continue the tackling issues that will improve quality of life.  
